Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Consensus Recommendation of “Buy” by Brokerages

Zealand Pharma A/S (OTCMKTS:ZLDPF) has been given an average rating of “Buy” by the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and five have given a strong buy recommendation to the company.

ZLDPF has been the topic of a number of recent analyst reports. BTIG Research raised shares of Zealand Pharma A/S to a “strong-buy” rating in a report on Friday, November 28th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a research report on Tuesday, December 16th.

Zealand Pharma A/S Price Performance

Shares of OTCMKTS:ZLDPF opened at $64.08 on Wednesday. The business’s 50 day moving average is $70.94 and its 200 day moving average is $70.22. Zealand Pharma A/S has a 12-month low of $49.98 and a 12-month high of $108.30. The stock has a market cap of $4.55 billion, a price-to-earnings ratio of 4.61 and a beta of 0.72. The company has a quick ratio of 14.10, a current ratio of 14.10 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($1.11) by $0.21. The firm had revenue of $7.76 million during the quarter, compared to analyst estimates of $4.54 million. Zealand Pharma A/S had a net margin of 71.79% and a return on equity of 55.76%. On average, sell-side analysts forecast that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.